Deals: Page 61

  • Horizon adds rare disease drugs in $800M Raptor deal

    The Irish specialty pharma will pay a small premium for Raptor, which markets Procysbi and Quinsair. 

    By • Sept. 12, 2016

  • Sanofi, Verily launch Onduo for diabetes care

    The big pharma teamed up with the Google subsidiary to launch a diabetes joint venture. 

    By Lisa LaMotta • Sept. 12, 2016

  • Gilead comments on split rumors

    Revenues from the big biotech's hepatitis C franchise have declined sharply, leading some to speculate the company could be worth more split in two. 

    By • Sept. 8, 2016
  • Image attribution tooltip
    pixabay
    Image attribution tooltip

    Allergan picks up gene therapy company

    Acquisition of RetroSense Therapeutics further builds out the Irish pharma's eye care portfolio. 

    By Lisa LaMotta • Sept. 6, 2016

  • Expanding pipeline, Amgen picks up multiple myeloma med

    The California biotech acquired global rights to an early-stage bispecific antibody from Boehringer Ingelheim. 

    By Suzanne Elvidge • Sept. 2, 2016
  • Image attribution tooltip
    Getty
    Image attribution tooltip

    Sunovion snaps up Cynapsus in $624M deal

    Cynapsus' lead candidate treats a common side effect experienced by patients with Parkinson's disease. 

    By • Sept. 1, 2016

  • Medivir plans year-end split

    The Swedish biotech will separate into two companies which will focus separately on commercial and R&D operations.

    By Lisa LaMotta • Aug. 31, 2016
  • Image attribution tooltip
    Myohan
    Image attribution tooltip

    Mallinckrodt sharpens specialty pharma focus

    IBA Molecular will pay $690 million to acquire Mallinckrodt's nuclear imaging business, which is mostly centered on the U.S. market. 

    By • Aug. 26, 2016
  • Image attribution tooltip
    Andrew Hecht
    Image attribution tooltip

    Cyon licenses PCSK9 inhibitor from Novartis

    The biotech is taking over development of big pharma drug as a treatment for sepsis, not cholesterol-lowering. 

    By Kirell Lakhman • Aug. 24, 2016

  • BioCardia finds alternative funding solution

    The California biotech is conducting a reverse merger to help fund a late-stage study. 

    By Lisa LaMotta • Aug. 24, 2016
  • Image attribution tooltip
    Depositphotos
    Image attribution tooltip

    Pfizer continues dealmaking with antibiotics buy

    The pharma giant will pay as much as $1.6 billion for AstraZeneca's small-molecule anti-infectives portfolio. 

    By • Aug. 24, 2016
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    DS Biopharma creates fibrotic spin out

    The privately held biotech is creating a new company to focus on fibrotic diseases. 

    By Lisa LaMotta • Aug. 23, 2016
  • Image attribution tooltip
    Depositphotos
    Image attribution tooltip

    Pfizer wins Medivation with $14B bid

    The big pharma adds to its cancer portfolio with a highly sought-after acquisition. 

    By Lisa LaMotta • Aug. 22, 2016
  • Image attribution tooltip
    NIH Image Bank, NIH
    Image attribution tooltip

    Roche, Eleven Bio eye the ocular market

    The pair team up on the biotech's IL-6 antagonist in a deal worth $270 million. 

    By • Aug. 19, 2016
  • Image attribution tooltip
    Depositphotos
    Image attribution tooltip

    Bayer, CRISPR christen Casebia

    The big pharma and the biotech reveal the details of the joint venture they established late last year. 

    By Lisa LaMotta • Aug. 19, 2016
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    FDA expedites Aspen's prostate drug ahead of merger

    The newly merged company will provide women's health, men's health and OTC products. 

    By • Aug. 18, 2016

  • Trek Therapeutics in-licenses Medivir hep C drug

     The agreement includes development and commercialization and has a global purview, with the exception of China, Taiwan, Hong Kong and Macai.

    By • Aug. 18, 2016

  • Rasna Therapeutics taps public market with merger

    The new company will trade on NASDAQ-OTC under the ticker ATVM.

    By • Aug. 18, 2016

  • Tioma lands $86M Series A for immunotherapy

    Formerly known as Vasculox, the biotech pulled in a large funding round to support its CD47 checkpoint inhibitor program. 

    By Lisa LaMotta • Aug. 16, 2016

  • Mallinckrodt plans regen med acquisition

    The UK specialty pharma has entered into a merger agreement with a privately-held regenerative medicine company. 

    By • Aug. 12, 2016
  • Image attribution tooltip
    Flickr; NIAID
    Image attribution tooltip

    Gilead licenses bi-specific tech from Danish biotech Genmab

    The major biotech hopes to develop a bi-specific antibody targeting HIV using Genmab's DuoBody platform.

    By • Aug. 12, 2016
  • Image attribution tooltip
    Flickr; Coolcaesar
    Image attribution tooltip

    Allergan makes a buy, but not the one you think

    Despite receiving an influx of over $33 billion in cash from the Teva deal, Allergan CEO Brent Saunders has indicated his preference for "stepping stone" deals. 

    By Lisa LaMotta • Aug. 11, 2016

  • Medivation bullish on Xtandi as PDUFA approaches

    CEO David Hung stayed mum on contract negotiations with potential suitors during the recent quarterly call. 

    By • Aug. 11, 2016

  • AstraZeneca bolsters stake in Moderna by $140 million

    As a result of the new equity investment, AstraZeneca now owns a 9% share in the messenger RNA company.

    By • Aug. 11, 2016
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Biogen's hemophilia spinoff has a shiny new name

    Bioverativ, named after its Biogen roots and the word 'veracity', is set to debut on public markets during the first half of 2017. 

    By Lisa LaMotta • Aug. 10, 2016